Literature DB >> 6848189

Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody.

D Colcher, M Zalutsky, W Kaplan, D Kufe, F Austin, J Schlom.   

Abstract

Monoclonal antibody B6.2 reacts with a protein found on the surface of primary and metastatic human mammary tumors. B6.2 immunoglobulin G (IgG) was purified, F(ab')2 and Fab' fragments were generated by pepsin digestion, and the IgG and its fragments were radiolabeled with 125I; all were successful in localizing human mammary tumors transplanted into athymic mice, with tumor:tissue ratios increasing over a 4-day period. The 125I-labeled IgG gave tumor:spleen, tumor:liver, and tumor:kidney ratios of greater than 10:1 and tumor:brain and tumor:muscle ratios of 50:1 to 110:1. The F(ab')2 fragment gave higher tumor:tissue ratios than did the IgG, with tumor:liver and tumor:spleen ratios of 15:1 to 20:1. No localization of the labeled B6.2 monoclonal antibody or its fragments was observed in athymic mice bearing a human melanoma or with isotype-identical control immunoglobulin or its fragments in athymic mice bearing the mammary tumors. Imaging experiments confirmed the ability of radiolabeled monoclonal antibody B6.2 and its fragments to detect the presence of transplanted human mammary tumor lesions of less than 0.4 cm without the aid of background subtraction manipulations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer.

Authors:  F Kraeber-Bodéré; A Mishra; P Thédrez; A Faivre-Chauvet; M Bardiès; S Imai; J Le Boterff; J F Chatal
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Genetic engineering of high affinity anti-human colorectal tumour mouse/human chimeric antibody.

Authors:  J Xiang; Z Chen
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.

Authors:  Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

4.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Localization of a membrane glycoprotein in benign fibrocystic disease and infiltrating duct carcinomas of the human breast with the use of a monoclonal antibody to guinea pig milk fat globule membrane.

Authors:  D E Greenwalt; V G Johnson; F P Kuhajda; J C Eggleston; I H Mather
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

6.  Antibody labeling with radioiodine and radiometals.

Authors:  Suprit Gupta; Surinder Batra; Maneesh Jain
Journal:  Methods Mol Biol       Date:  2014

7.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

Review 8.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Development of new anti-cancer drugs.

Authors:  H M Pinedo
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

10.  High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts.

Authors:  R L Wahl; B S Wilson; M Liebert; W H Beierwaltes
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.